CHELMSFORD, Mass., Dec. 3, 2020 /PRNewswire/ -- Brooks
Automation, Inc. (Nasdaq: BRKS) today announced that it has
acquired Trans-Hit Biomarkers Inc. (THB), a worldwide biospecimen
procurement service provider based in Montreal Canada. THB has an extensive
collection capability for biospecimens and clinical samples through
a worldwide partner network of clinical sites and biobanks. THB is
enabled by a team with an extensive background in biomedical
research that advises biopharma and diagnostic clients on the best
solutions to design, organize and conduct sample collections in
various fields including oncology and infectious
diseases.
Steve Schwartz, president and CEO
of Brooks commented, "With a decade of experience solving
customers' research needs with fit-for-purpose biospecimens, THB is
a great addition to our life sciences business. Our combined
strength in biospecimen procurement, sample management, and genomic
analytical services will add value to our customers, which we
believe will provide another growth vector to Brooks Life Sciences
Services business."
Dr. Pascal Puchois, the founder and Chief Executive Officer of
THB, will continue to lead the business as part of Brooks Life
Sciences. The Company expects the acquisition to be modestly
accretive to earnings immediately. Specific terms of the
acquisition were not disclosed.
About Brooks Automation
Brooks (Nasdaq: BRKS) is a leading provider of life science
sample-based solutions and semiconductor manufacturing solutions
worldwide. The Company's Life Sciences business provides a
full suite of reliable cold-chain sample management solutions and
genomic services across areas such as drug development, clinical
research and advanced cell therapies for the industry's top
pharmaceutical, biotech, academic and healthcare institutions
globally. Brooks Life Sciences' GENEWIZ division is a leading
provider of gene sequencing and gene synthesis services. With
over 40 years as a partner to the semiconductor manufacturing
industry, Brooks is a provider of industry-leading precision vacuum
robotics, integrated automation systems and contamination control
solutions to the world's leading semiconductor chip makers and
equipment manufacturers. Brooks is headquartered in
Chelmsford, MA, with operations in
North America, Europe and Asia. For more information,
visit www.brooks.com.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are
forward-looking statements made under Section 21E of the Securities
Exchange Act of 1934. These statements are neither promises nor
guarantees but involve risks and uncertainties, both known and
unknown, that could cause Brooks' financial and business results to
differ materially from our expectations. They are based on the
facts known to management at the time they are made. These
forward-looking statements include but are not limited to
statements about the benefits of the Company's acquisition of
Trans-Hit Biomarkers Inc. and the expected value of the acquisition
to the Company. Factors that could cause results to differ from our
expectations include the following: the impact of the
COVID-19 global pandemic on the markets we and Trans-Hit Biomarkers
Inc. serve; uncertainties in global political and economic
conditions, our ability to integrate the acquired business and
other factors and other risks, including those that we have
described in our filings with the Securities and Exchange
Commission, including but not limited to our Annual Report on Form
10-K, current reports on Form 8-K and our quarterly reports on Form
10-Q.
INVESTOR CONTACTS:
Mark Namaroff
Director, Investor Relations
Brooks Automation
978.262.2635
mark.namaroff@brooks.com
Sherry Dinsmore
Brooks Automation
978.262.4301
sherry.dinsmore@brooks.com
John Mills
Managing Partner
ICR, LLC
646.277.1254
john.mills@icrinc.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/brooks-announces-the-acquisition-of-trans-hit-biomarkers-301186140.html
SOURCE Brooks Automation